Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Stenoparib - Allarity Therapeutics

Next Previous
Drug Profile

Stenoparib - Allarity Therapeutics

Alternative Names: 2X-121; 2X-121/PARPi; E-7449; MGI 25036

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Allarity Therapeutics
  • Class Antineoplastics; Antivirals; Isoindoles; Pyridazines; Quinazolines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors; Tankyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Ovarian cancer
  • Phase I/II Solid tumours
  • No development reported B-cell lymphoma; COVID 2019 infections; Neuroblastoma; Renal cancer; Sarcoma

Most Recent Events

  • 04 Jun 2025 Allarity Therapeutics enters into a research agreement with Indiana Biosciences Research Institute for understanding of the dual mechanism of action of Stenoparib
  • 09 May 2025 Allarity Therapeutics plans a phase II trial for Small-cell lung cancer (Combination therapy) by the third quarter of 2025
  • 17 Mar 2025 Adverse events data from a phase II (PREDICT 2X-121)trial in Ovarian cancer released by Allarity Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top